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TREATMENT OF CONGESTIVE HEART FAILURE WITH 
3-BENZYL DIHYDROFLUMETHIAZIDE: 
PRELIMINARY REPORT 
GERALD M . BRENEMAN, M.D.* AND JOHN W . KEYES, M.D.* 
Since the introduction of chlorothiazide in 1957,^  several analogues of the 
benzothiadiazine series have been made available for the treatment of edematous 
states, and most widely applied in the treatment of congestive heart failure. Hydro-
chlorothiazide, flumethiazide and hydroflumethiazide, in addition to the former, have 
all been reported to be potent oral diuretic agents. '^' 
Toxicity to this group of drugs has been low, despite their wide clinical use. 
The most serious side effects are related to depletion of electrolytes, particularly of 
potassium and chloride. Efforts to develop more potent agents with fewer side 
effects, however, will undoubtedly continue. 
A new substituted benzothiadiazine derivative, 3-benzyl dihydroflumethiazide, 
has recentiy been made available for clinical trial (Figure 1). Preliminary animal 
studies and clinical tests indicated that its diuretic activity was significantly greater 
than that of chlorothiazide and dihydroflumethiazide.^ 
Cl 
HjNOjS HjNOjS 
^CHCH, 
KH 
0 „ 
Chloroth iaz ide 5- Benzyl DihydrofI tunethiazide 
Figure I Structural Formulae 
METHOD 
3-benzyl dihydroflumethiazide was administered to a group of 21 patients with 
congestive heart failure. The subjects were divided into three groups as determined 
by the severity of the congestive failure and response to previous diuretic therapy 
(Table 1). Grade I patients had mild to moderate degrees of congestive heart failure. 
Table 1 
Type of congestive heart failure of 21 patients 
Etiology Grade I Grade I I Gradelll Tolal 
Arteriosclerotic 2 9 2 13 
Rheumatic (I 6 0 6 
Congenital 1 1 0 2 
TOTAL 3 16 2 21 
manifested by dyspnea, moist basilar rales and hepatic congestion. Grade I I patients 
* Division of Cardiovascular Disease. 
Drug material for this study was supplied by E. R. Squibb & Sons, Division of Olin Mathieson 
Chemical Corp., New Brunswick, N . J. 
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had severe degrees of heart failure with edema and/or ascites, while Grade I I I 
patients consisted of those who had become resistant or refractive to previous diuretic 
therapy. 
Thirteen patients had arteriosclerotic heart disease, 6 had rheumatic heart 
disease and there were 2 cases of congenital heart disease. Al l pafients were digitalized 
and maintained on 400 to 1600 mgm. sodium diets as indicated. The majority had 
received previous diuretic therapy, mercurials and/or one of the benzothiadiazine 
derivatives. 
Seventeen patients were hospitalized and actively treated because of their de-
compensated status. A daily weight was obtained as well as regular blood counts, 
urinalyses and blood urea nitrogen determinations. Serum electrolytes were determined 
prior to and immediately after each period of diuretic administration. In 4 cases 
the drug was substituted for a previous diuretic agent as maintenance therapy in 
the out-patient clinic. 
The dmg was administered in a dosage of one 5 mgm. tablet two to three 
times daily for a period of two to three days, followed by a rest period of the same 
duration. In a few instances of severe congestive heart failure, the drug was given 
for a longer consecutive period. Patients previously treated with chlorothiazide or 
hydrochlorothiazide were given 5 mgm. of the new agent in place of 500 mgm. 
of the former or 50 mgm. of the latter. Ammonium chloride was given concurrently 
in about one-half of the cases while supplemental potassium salts were used in 
only a few instances. 
RESULTS 
Grade I . Two patients with arteriosclerotic heart disease and one with congenital 
heart disease (aortic stenosis) had early congestive heart failure. One had received 
no previous diuretic therapy. A l l had a good response with a weight loss of 2 to 
7 pounds. No marked change in serum electrolytes was noted. One patient continued 
to have diuresis on the third day after the dmg was discontinued, a phenomenon 
we have previously noted with hydrochlorothiazide, and described again in Case 
2 below. 
Grade / / . Sixteen patients were classified as having Grade I I congestive heart 
failure, 9 with arteriosclerotic heart disease, 6 with rheumatic heart disease and 1 
with congenital heart disease (atrial septal defect). Of 12 hospitalized patients, 
all had a good diuresis with weight losses ranging from 4 to 25 pounds. Ten of 
these 12 had received prior therapy with mercurial or the benzothiadiazine diuretics 
and all responded equally well or better to 3-benzyl dihydroflumethiazide. No 
toxicity was noted and no severe electrolyte depletion occurred. All showed evidence 
of a mild hypochloremic alkalosis as noted with the prior thiazide derivatives. 
Case 1. W. G. was a 48 year old man who had known rheumatic heart 
disease with aortic incompetency since the age of 18. Nine months prior to admission 
he developed atrial fibrillation and signs of congestive heart failure. Despite con-
version of the arrhythmia on two occasions a sinus rhythm could not be maintained. 
He did well for a time on digitalis, a low sodium diet and intermittent administration 
of chlorothiazide and occasional injections of a mercurial diuretic. 
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He was admitted to the hospital on Sept. 2, 1959, because of increasingly severe 
exertional dyspnea, nocturnal dyspnea and orthopnea. The blood pressure was 132/62. 
There was atrial fibrillation at a rate of 84 per minute and aortic systolic and 
diastolic murmurs with an absent A2. There were medium moist rales in both lung 
bases and the liver edge was palpable 5 cm. below the costal margin and was tender. 
He was continued on digitoxin 0.1 mgm. daily and a 400 mgm. sodium diet. 
On the first day of administration of 3-benzyl dihydroflumethiazide he lost 10 pounds 
and felt much improved. He lost a total of 20 pounds during the 8 days of 
intermittent administration of the drug (Figure 2), and the congestive failure was 
completely controlled. Slight hypochloremic alkalosis was the only change in electro-
lytes noted despite the fact that no supplementary chloride or potassium was given. 
195 _ 
190 
Electrolytes 
I n i t i a l Ha-137 K-k.O Cl-98 CO2-2I.O 
Pinal Na-136 K-if.7 CI-90 CO2-26.I 
I chlorothiazide 500 mgm. 
^ 3-BDF 15 mgm. 
Figure II . Weight loss and electrolyte change in W. G. (Case 1) on 3- benzyl dihydroflumethiazide. 
Complete control of congestive failure in 10 days. 
One Grade I I patient showed the continued diuresis following cessation of drug 
administration referred to above and warrants a brief case report. 
Case 2. C. F. was a 54 year old Negro male who had been treated at this 
hospital in 1953 for an acute anterior myocardial infarcfion. In January 1956 he 
first developed congestive heart failure and in the ensuing years was hospitalized 
on several occasions for the treatment of exacerbations of chronic congestive heart 
failure. He was unable to work since October 1957. 
He was re-admitted on July 5, 1959, because of an increase in dyspnea, ankle 
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edema and loss of appetite. The heart was grossly enlarged and there was a gallop 
rhythm with frequent premature systoles. The liver edge was palpable 6 cm. below 
the costal margin and tender. There were bilateral moist basilar rales and 3-|-
pretibial pitting edema. 
Digitalis and a 400 mgm. sodium diet were continued. After four days of 
stable weight, 3-benzyl dihydroflumethiazide was given in a dosage of 5 mgm. three 
times daily. A prompt diuresis resulted. (Figure 3) After 7 consecutive days of 
drug administration it was discontinued, but diuresis continued and he lost an ad-
ditional 11 pounds of weight in the next 6 days without any other change in therapy. 
155 _ Electrolytes 
Initial Na-157 K-5.8 Cl-99 CO^-2l.O 
Pinal Na-132 K-5.7 01-100 CO^~l6.6 
3-BDF 15 mgm. daily 
125 
Figure I I I . Weight loss and electrolyte change in C. E. (Case 2) with 3- benzyl dihydroflumethiazide. 
Note continued diuresis following cessation of drug. Congestive failure completely controlled. 
Four patients with Grade I I congestive heart failure were treated in the out-
patient department. Two patients with rheumatic heart disease were well controlled 
on chlorothiazide and continued to do equally well when given the new maintenance 
diuretic. Two patients with arteriosclerotic heart disease and near the terminal stage 
of their disease were poorly controlled on a maintenance dose of chlorothiazide and 
intermittent injections of mercurial diuretics. No improvement was noted when 3-
benzyl dihydroflumethiazide was substituted for the chlorothiazide. 
Grade H I . Two patients with arteriosclerotic heart disease and severe advanced 
congestive heart failure had become refractive to mercurial diuretics, chlorothiazide 
and hydrochlorothiazide. The serum electrolyte patterns were within the normal 
range. Neither showed any response to 3-benzyl dihydroflumethiazide. 
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COMMENT 
The thiazide derivatives produce diuresis as a result of blockage of the tubular 
transport mechanisms involved in the reabsorption of sodium, chloride, and, to a 
lesser degree, of potassium and bicarbonate. The electrolyte excretion patterns are 
basically similar, though definite differences have been noted." Beyer and Baer 
are of the opinion that this does not necessarily indicate a difference in pharmacologic 
action, but is more likely related to differences in the back diffusion of chlorfde 
and bicarbonate secondary to differences in distribution of the drug.' 
3-benzyl dihydroflumethiazide would seem to share this same mechanism of 
action. On a milligram for milligram basis, however, it is a more potent agent than 
chlorothiazide or hydrochlorothiazide, being approximately 100 times more potent 
than the former and 10 times more potent than the latter. 
Mild hypochloremia was noted in all cases in which diuretic responses were 
obtained. This was easily corrected by the administration of ammonium chloride. 
No significant reduction in the levels of serum sodium or potassium was observed. 
No change was noted in the blood count, urinalysis or BUN of any case. 
3-benzyl dihydroflumethiazide was well tolerated by all patients in this series. 
No side effects were noted. A low incidence of nausea, vomiting and weakness 
has been reported previously with chlorothiazide and hydrochlorothiazide. 
These results indicate that 3-benzyl dihydroflumethiazide is a potent oral diuretic 
agent. A decreased incidence of side effects, if substantiated by further study, would 
be a decided advantage over previous thiazide derivatives. Further investigation may 
also indicate that there is less of a tendency to depletion of sodium and potassium, 
though these should be watched for in long continued use of this agent as with the 
other thiazide derivatives. This is particularly true of the patient with advanced 
cardiac or hepatic disease. 
SUMMARY 
A new benzothiadiazine derivative, 3-benzyl dihydroflumethiazide, was admin-
istered to a group of 21 patients with varying degrees of congestive heart failure. 
Results of this preliminary study indicate that it is an active diuretic agent ap-
proximately 100 times more potent than chlorothiazide. No toxicity or serious elect-
rolyte disturbances were noted. 
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